Medical Journal Publications
Association of Reproductive Health Professionals
A New View of Women's Sexual Health in Midlife and Beyond
May 2005: "A botanical feminine massage oil formulated to enhance female sexual pleasure and arousal when applied to the vulva, Zestraź was compared in a randomized, doubleblind, crossover study with placebo oil in 10 women with and 10 women without female sexual arousal disorder (FSAD). Both women with and without FSAD showed statistically significant improvements compared with placebo in levels of arousal and desire, satisfaction with arousal, genital sensation, the ability to have orgasms, and sexual pleasure. A greater response was found in women with the disorder compared with women who did not complain of arousal problems."
View
entire
article: A New View of Women's Sexual Health in Midlife and Beyond Excerpt
Female Sexual Dysfunction: Principles of Diagnosis and Therapy
March 2005, Obstetrical and Gynecological Survey published a Continuing Medical Education (CME) Review Article that acknowledges the benefits of Zestraź for both arousal and orgasmic difficulties. The objective of the CME Review Article titled "Female Sexual Dysfunction: Principles of Therapy" is to provide the most current clinical information available to Obstetricians and Gynecologists on the topic of female sexual dysfunction and the principles of diagnosis and therapy.
The CME Review Article cites a clinical trial conducted by QualiLife Pharmaceuticals titled "Randomized Placebo-Controlled Double Blind, Crossover Design Trial of the Efficacy and Safety of Zestraź for Women in Women With, and Without Female Sexual Arousal Disorder (FSAD)." The study of 20 women showed improvement in level of desire, arousal, sensation, pleasure and ability to have orgasms in both normal and FSAD patients using Zestraź, as compared with placebo. Zestraź is the only product listed in the CME Review Article that has published clinical study results and no known negative effects.
View
entire
article: Female Sexual Dysfunction: Principles of Diagnosis and Therapy
PDF (382kb)
Dietary supplements for female sexual dysfunction
"A randomized, double-blind, placebo-controlled trial studied the effects of Zestraź in 20 women with and without FSAD.23 Applicants were evaluated with the FSFI and FSDS questionnaires. Women with FSAD had baseline scores of 4060 on the FSDS, and non-FSAD women had baseline scores of <40 on the FSDS. (The FSDS ranges from 0 to 80, with lower scores generally indicating normal function.) All participants were allowed to continue current medications, including antidepressants, nutritional supplements, and hormone replacement therapy. Sexual pain or an FSDS score of >60 would exclude patients from participation. Each patient was given five vials of Zestraź or placebo and a diary (the Female Sexual Encounter Profile [FSEP]). After the patients used all five vials, they returned and completed the FSFI, the FSDS, two global assessment questionnaires (GAQs), and the QualiLife Consumer Testing Survey (QCTS). Then they received the crossover vials and a new diary and returned to complete the questionnaires again. Zestraź produced significant improvement in FSEP, FSFI, GAQ, and QCTS scores. The primary outcome measure, sexual arousal, showed a mean ± S.D. improvement (on a 01 scale) of 0.22 ± 0.28 (p = 0.03). There were no significant changes in FSDS scores. In addition, the researchers compared data between patients taking and not taking SSRIs; there was no significant difference. It was concluded that Zestraź improved sexual function in all subjects, regardless of FSAD diagnosis or SSRI use. Some patients reported that Zestraź caused mild burning or tingling that resolved within 30 minutes. No other adverse effects were reported."
View
American Journal of Health
- (Full Text Article).
Randomized, Placebo-Controlled, Double Blind, Crossover Design Trial of the Efficacy and Safety of Zestraź for Women in Women With and Without Female Sexual Arousal Disorder
Zestraź for Women is a botanical feminine massage oil formulated to enhance female sexual pleasure and arousal when applied to the vulva. We conducted this randomized, double-blinded, crossover study to evaluate the efficacy and safety of Zestraź for Women compared to placebo oil in 10 women with and 10 women without female sexual arousal disorder (FSAD) in conditions of home use in conjunction with sexual activities...
Read
abstract from the 12-page JSMT article
Female Sexual Dysfunction - Potential for Pharmacotherapy
The act of sex includes a woman's sexual self and self-image, intimate relationships, family, society and culture. The complexities of her environment, sexual and partner history, past relationships, mental health status, current medical problems and hormonal status all play a role. An interdisciplinary consensus conference panel expanded the former Diagnostic and Statistical Manual of Mental Disorders-IV classifications of female sexual dysfunction to include psychogenic and organic causes of desire, arousal, orgasm and sexual pain disorders that cause personal distress...
View
Excerpts from the Drugs Journal Article
The National Association of Nurse Practitioners in Women's Health - A Practical Journal for Nurse Practitioners I can't tell you how many patients I've also heard from, expecially when, everywhere they turn, from Forbes to Redbook, they (or their significant other) read about a supposedly "harmless" natural product that claims to enhance desire, arousal, lubrication, orgasm, and satisfaction. This prompts me to quote a common adage, "If it sounds too good to be true, it probably is."
View
the Women's Health Care Article
Your Cart
